- Home
- NTIP vs MURA Comparison
NTIP vs MURA Comparison
Compare NTIP & MURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NTIP
- MURA
- Stock Information
- Founded
- NTIP 1990
- MURA 2013
- Country
- NTIP United States
- MURA Ireland
- Employees
- NTIP N/A
- MURA N/A
- Industry
- NTIP Multi-Sector Companies
- MURA
- Sector
- NTIP Miscellaneous
- MURA
- Exchange
- NTIP Nasdaq
- MURA Nasdaq
- Market Cap
- NTIP 32.0M
- MURA 36.0M
- IPO Year
- NTIP 1998
- MURA N/A
- Fundamental
- Price
- NTIP N/A
- MURA $2.08
- Analyst Decision
- NTIP
- MURA Buy
- Analyst Count
- NTIP 0
- MURA 2
- Target Price
- NTIP N/A
- MURA $6.00
- AVG Volume (30 Days)
- NTIP 39.0K
- MURA 157.1K
- Earning Date
- NTIP 10-23-2025
- MURA 11-12-2025
- Dividend Yield
- NTIP 6.49%
- MURA N/A
- EPS Growth
- NTIP N/A
- MURA N/A
- EPS
- NTIP N/A
- MURA N/A
- Revenue
- NTIP $150,000.00
- MURA N/A
- Revenue This Year
- NTIP N/A
- MURA N/A
- Revenue Next Year
- NTIP N/A
- MURA N/A
- P/E Ratio
- NTIP N/A
- MURA N/A
- Revenue Growth
- NTIP N/A
- MURA N/A
- 52 Week Low
- NTIP $1.16
- MURA $0.95
- 52 Week High
- NTIP $1.90
- MURA $4.74
- Technical
- Relative Strength Index (RSI)
- NTIP N/A
- MURA 53.11
- Support Level
- NTIP N/A
- MURA $2.06
- Resistance Level
- NTIP N/A
- MURA $2.12
- Average True Range (ATR)
- NTIP 0.00
- MURA 0.02
- MACD
- NTIP 0.00
- MURA -0.00
- Stochastic Oscillator
- NTIP 0.00
- MURA 41.67
About NTIP Network-1 Technologies Inc.
Network-1 Technologies Inc is involved in the business of the development, licensing, and protection of intellectual property assets. The company's current plan includes continuing to pursue licensing opportunities for its intellectual property assets.
About MURA Mural Oncology plc
Mural Oncology PLC is a clinical-stage oncology company whose entire business is focused on discovering and developing immunotherapies that may meaningfully improve the lives of patients with cancer. By leveraging its core competencies in immune cell modulation and protein engineering, It has developed a portfolio of novel, investigational cytokine therapies designed to address areas of unmet need for patients with a variety of cancers. Its product candidate, Nemvaleukin is an investigational, engineered interleukin-2 cytokine designed to capture and expand the therapeutic benefits of high-dose recombinant human IL-2 while mitigating its hallmark toxicities.